MIRA — Mira Pharmaceuticals Share News
0.000.00%
Last trade - 00:00Brief: Mira Pharmaceuticals Inc - Announces Positive Study Results For Ketamir-2
Brief: Mira Pharmaceuticals Inc - Enrolls First Subjects In Phase 1 Trial For Ketamir-2 - SEC Filing
U.S. STOCKS ON THE MOVE-Tesla, Pinterest, IBM
Mira Pharma Falls On All: stock deal for SKNY Pharma
Brief: Mira Pharmaceuticals Inc To Acquire Skny Pharmaceuticals - SEC Filing
Brief: Mira Pharmaceuticals succesfully develops topical version of its therapy for localized neuropathic and inflammatory pain
Brief: Mira Pharmaceuticals Announces Approval And Initiation Of Phase 1 Clinical Trial For Ketamir-2 In Neuropathic Pain
Brief: Mira Pharmaceuticals May Offer,Sell Shares Of Common Stock Of Up To $75 Million From Time To Time
U.S. STOCKS ON THE MOVE-Tesla, Icahn Enterprises, Boeing
U.S. STOCKS ON THE MOVE-Boeing, Tesla, Icahn Enterprises
U.S. STOCKS ON THE MOVE-XPeng, SolarEdge, SentinelOne
Mira Pharma Rises On Positive Pre: clinical data for pain drug
Brief: Mira Pharmaceuticals Achieves 100% Reversal Of Neuropathic Pain
Brief: Mira Pharmaceuticals Achieves 100% Reversal Of Neuropathic Pain With Oral Ketamir-2
Brief: Mira Pharmaceuticals Ketamir-2 Shows Promising Safety Profile In Comparison To Traditional Ketamine In Preclinical Testing
Brief: Mira Pharmaceuticals Announces Positive Preclinical Study Results For Its Novel Oral Ketamine Analog, Ketamir-2, Paving Way For IND Submission Later This Year
Brief: Mira Pharmaceuticals Inc DEA Rules Mira-55, A Novel Oral Pharmaceutical Marijuana Analog, Is Not Classified As A Controlled Substance
Brief: Mira Pharmaceuticals In Discussions With Memorial Sloan Kettering To Collaborate On Preclinical Cancer Pain Model Utilizing The Company's Novel Oral Ketamine Analog
Brief: Mira Pharmaceuticals Advances Preclinical Trials Towards An Ind Submission This Year For Ketamir-2, A Differentiated Oral Ketamine Analog